Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Retatrutide
A GIP/GLP-1/glucagon triple agonist studied in obesity research.
- Half-life (approx.)
- ~6 days (approx., subQ)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 5, 10, 20 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist showing substantial weight-loss endpoints in phase 2 obesity trials. It represents the next generation beyond dual agonists like tirzepatide in incretin research. Triple incretin/glucagon agonist (LY3437943) in advanced phase 2 metabolic trials.
Structure & identity
GIP/GLP-1/glucagon triple agonist peptide
Status: Investigational (LY3437943).
Mechanism
Retatrutide combines GIP, GLP-1, and glucagon receptor agonism to target satiety, insulin sensitization, and energy expenditure pathways in metabolic research.
Triple GIP/GLP-1/glucagon agonist combining satiety, insulin sensitization, and energy expenditure. Simultaneous GIP, GLP-1, and glucagon receptor activation targets weight and hepatic fat endpoints.
Studies & clinical programs
Phase 2 metabolic trials (LY3437943)(Phase 2)
Obesity and type 2 diabetes
- Triple GIP/GLP-1/glucagon agonism explored for weight and glycemic endpoints.
- Compared with dual incretin agents in emerging trial literature.
Source: Investigational retatrutide program
Research models in literature
- Phase 2 obesity trials
- Phase 2 MASH trials
Literature highlights
- Triple GIP/GLP-1/glucagon agonist (LY3437943) in phase 2 obesity and MASH trials.
- Energy expenditure and hepatic fat endpoints supplement weight-loss readouts.
- Investigational multi-incretin class — compared with dual agonists in trial literature.
Combination research notes
Trial landscape compares retatrutide with tirzepatide and survodutide dual agonists.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
| 20 | 2 | 10000.0 | 1 | 2.5 | 5 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; potency differs from GLP-1-only agents.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance